Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
An update from Nordic Nanovector ASA ( (DE:8NN) ) is now available.
Thor Medical ASA has announced the completion of an extraordinary general meeting, which approved the issuance of 23,396,380 new shares as part of the second tranche of a private placement. This action involved a share lending agreement with Carnegie AS and Scatec Innovation AS, which lent shares for the settlement of the private placement. As a result, Scatec Innovation AS’s shareholding temporarily decreased below the 20% threshold of the company’s issued share capital and votes, although its aggregated holding, including controlling interests, remains above this threshold. The move is significant as it impacts Scatec Innovation AS’s influence within Thor Medical and aligns with regulatory disclosure requirements.
More about Nordic Nanovector ASA
Thor Medical ASA is an emerging supplier in the radiopharmaceutical industry, specializing in radionuclides, primarily alpha particle emitters, derived from naturally occurring thorium. The company prides itself on a proprietary production process that does not require irradiation or nuclear reactors, ensuring a reliable, environmentally friendly, and cost-efficient supply of alpha-emitters. Thor Medical is headquartered in Oslo, Norway, and is listed on the Oslo Stock Exchange under the ticker symbol ‘TRMED’.
YTD Price Performance: 2.74%
Average Trading Volume: 5,336
Technical Sentiment Consensus Rating: Sell
Current Market Cap: €64.24M
For detailed information about 8NN stock, go to TipRanks’ Stock Analysis page.
